Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3931438 | 1.00 | KMT2A (0.43) | KMT2AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL18613637 | 0.82 | KMT2A (0.43) | KMT2AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL18613639 | 0.82 | KMT2A (0.43) | KMT2AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL29551120 | 0.82 | NNMT (0.50) | KMT2AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL20439701 | 0.82 | NNMT (0.50) | KMT2AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL3785660 | 0.80 | MAPT (0.46) | KMT2AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL3785658 | 0.80 | MAPT (0.46) | KMT2AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL27176728 | 0.77 | ALDH1A1 (0.56) | KMT2AALDH1A1KDM4EMAPTMEN1 | |
| SCHEMBL2599961 | 0.76 | ERN1 (0.51) | KMT2AALDH1A1KDM4EMEN1ERN1 | |
| SCHEMBL8343027 | 0.74 | ALDH1A1 (0.36) | KMT2AALDH1A1KDM4EMAPTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | KMT2A 4680/4885ALDH1A1 422/4885KDM4E 3977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.